Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Robbins Farley

Robbins Farley lessened its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,836 shares of the company's stock after selling 5,418 shares during the quarter. Robbins Farley owned about 0.06% of Prestige Consumer Healthcare worth $2,174,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its stake in shares of Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock worth $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC boosted its stake in Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company's stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank boosted its stake in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock worth $46,000 after purchasing an additional 181 shares in the last quarter. International Assets Investment Management LLC grew its position in Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock worth $83,000 after purchasing an additional 1,138 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in Prestige Consumer Healthcare by 49.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,163 shares of the company's stock valued at $84,000 after purchasing an additional 387 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PBH. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Friday, January 24th. DA Davidson increased their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday. Sidoti downgraded Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price for the company. in a report on Monday, December 9th. Finally, Canaccord Genuity Group increased their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and a consensus price target of $92.50.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH traded down $0.39 during trading on Friday, reaching $86.96. 523,063 shares of the company traded hands, compared to its average volume of 315,503. Prestige Consumer Healthcare Inc. has a 12-month low of $60.00 and a 12-month high of $88.36. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The stock has a market cap of $4.30 billion, a P/E ratio of 21.16, a PEG ratio of 2.15 and a beta of 0.50. The firm's fifty day simple moving average is $79.19 and its 200 day simple moving average is $75.34.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. As a group, research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.46 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares in the company, valued at $1,505,930. This represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 in the last three months. Company insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.